Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential

Oncogene

Volumn 35, Issue 37, 2016, Pages 4891-4902

  Hung, M H ^a,b   Chen, Y L ^c,d   Chu, P Y ^e,f   Shih, C T ^g   Yu, H C ^g   Tai, W T ^g   Shiau, C W ^b   Chen, K F ^g  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^e SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^f FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; RECOMBINANT PROTEIN; SET PROTEIN; SORAFENIB; UNCLASSIFIED DRUG; [N 4 (3 ETHYNYLPHENYL) 6,7 DIMETHOXY N2 (4 PHENOXYPHENYL) QUINAZOLINE 2,4 DIAMINE]; CARBANILAMIDE DERIVATIVE; CHAPERONE; N4-(3-ETHYNYLPHENYL)-6,7-DIMETHOXY-N2-(4-PHENOXYPHENYL)QUINAZOLINE-2,4-DIAMINE; NICOTINAMIDE; QUINAZOLINE DERIVATIVE; SET PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PATIENT; CELL DEATH; CELL GROWTH; CLINICAL FEATURE; CLINICAL OUTCOME; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RECURRENCE FREE SURVIVAL; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; PATHOLOGY; PROGNOSIS; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE CHAPERONES; HUMANS; LIVER NEOPLASMS; MALE; MICE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; QUINAZOLINES; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84958063743     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.21     Document Type: Article

References (51)

1. El-Serag HB. Hepatocellular carcinoma. New Engl J Med 2011; 365: 1118-1127.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
4. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
5. Bononi A, Agnoletto C, De Marchi E, Marchi S, Patergnani S, Bonora M et al. Protein kinases and phosphatases in the control of cell fate. Enzyme Res 2011; 2011: 329098.
6. Perrotti D, Neviani P. Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol 2013; 14: e229-e238.
7. Suganuma M, Fujiki H, Suguri H, Yoshizawa S, Hirota M, Nakayasu M et al. Okadaic acid: an additional non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter. Proc Natl Acad Sci USA 1988; 85: 1768-1771.
8. Haystead TA, Sim AT, Carling D, Honnor RC, Tsukitani Y, Cohen P et al. Effects of the tumour promoter okadaic acid on intracellular protein phosphorylation and metabolism. Nature 1989; 337: 78-81.
9. Arroyo JD, Hahn WC. Involvement of PP2A in viral and cellular transformation. Oncogene 2005; 24: 7746-7755.
10. Chen W, Possemato R, Campbell KT, Plattner CA, Pallas DC, Hahn WC. Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell 2004; 5: 127-136.
11. Mumby M. PP2A: unveiling a reluctant tumor suppressor. Cell 2007; 130: 21-24.
12. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T et al. CIP2A inhibits PP2A in human malignancies. Cell 2007; 130: 51-62.
13. Cristobal I, Rincon R, Manso R, Carames C, Zazo S, Madoz-Gurpide J et al. Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer. Clin Cancer Res 2015; 21: 347-356.
14. Chen W, Wang Z, Jiang C, Ding Y. PP2A-mediated anticancer therapy. Gastroenterol Res Pract 2013; 2013: 675429.
15. Carlson SG, Eng E, Kim EG, Perlman EJ, Copeland TD, Ballermann BJ. Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms' tumor. J Am Soc Nephrol 1998; 9: 1873-1880.
16. Li M, Makkinje A, Damuni Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem 1996; 271: 11059-11062.
17. Cristobal I, Garcia-Orti L, Cirauqui C, Cortes-Lavaud X, Garcia-Sanchez MA, Calasanz MJ et al. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica 2012; 97: 543-550.
18. Janghorban M, Farrell AS, Allen-Petersen BL, Pelz C, Daniel CJ, Oddo J et al. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer. Proc Natl Acad Sci USA 2014; 111: 9157-9162.
19. Liu GP, Wei W, Zhou X, Zhang Y, Shi HH, Yin J et al. I(2)(PP2A) regulates p53 and Akt correlatively and leads the neurons to abort apoptosis. Neurobiol Aging 2012; 33: 254-264.
20. Christensen DJ, Ohkubo N, Oddo J, Van Kanegan MJ, Neil J, Li F et al. Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J Immunol (Baltimore, MD: 1950) 2011; 186: 2535-2542.
21. Leopoldino AM, Squarize CH, Garcia CB, Almeida LO, Pestana CR, Polizello AC et al. Accumulation of the SET protein in HEK293T cells and mild oxidative stress: cell survival or death signaling. Mol Cell Biochem 2012; 363: 65-74.
22. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005; 8: 355-368.
23. Junttila MR, Li SP, Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 2008; 22: 954-965.
24. Al-Murrani SW, Woodgett JR, Damuni Z. Expression of I2PP2A, an inhibitor of protein phosphatase 2A, induces c-Jun and AP-1 activity. Biochem J 1999; 341: 293-298.
25. Fukukawa C, Shima H, Tanuma N, Ogawa K, Kikuchi K. Up-regulation of I-2(PP2A)/SET gene expression in rat primary hepatomas and regenerating livers. Cancer Lett 2000; 161: 89-95.
26. Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, Vitek MP. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene 2011; 30: 2504-2513.
27. Kubota D, Yoshida A, Kawai A, Kondo T. Proteomics identified overexpression of SET oncogene product and possible therapeutic utility of protein phosphatase 2A in alveolar soft part sarcoma. J Proteome Res 2014; 13: 2250-2261.
28. Cristobal I, Rincon R, Manso R, Carames C, Zazo S, Madoz-Gurpide J et al. Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer. Clin Cancer Res 2015; 21: 347-356.
29. Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR et al. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 2010; 29: 6257-6266.
30. Yu HC, Chen HJ, Chang YL, Liu CY, Shiau CW, Cheng AL et al. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma. Biochem Pharmacol 2013; 85: 356-366.
31. Chen KF, Pao KC, Su JC, Chou YC, Liu CY, Chen HJ et al. Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity. Bioorg Med Chem 2012; 20: 6144-6153.
32. Yu HC, Hung MH, Chen YL, Chu PY, Wang CY, Chao TT et al. Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A. Cell Death Dis 2014; 5: e1359.
33. Arnaud L, Chen S, Liu F, Li B, Khatoon S, Grundke-Iqbal I et al. Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET. FEBS Lett 2011; 585: 2653-2659.
34. Soderberg O, Gullberg M, Jarvius M, Ridderstrale K, Leuchowius KJ, Jarvius J et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 2006; 3: 995-1000.
35. Patching SG. Surface plasmon resonance spectroscopy for characterisation of membrane protein-ligand interactions and its potential for drug discovery. Biochim Biophys Acta 2014; 1838: 43-55.
36. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 2008; 8: 187-198.
37. Chen KF, Chen HL, Tai WT, Feng WC, Hsu CH, Chen PJ et al. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther 2011; 337: 155-161.
38. Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M et al. STORM: a phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). J Clin Oncol 2014; 32: 2014 (suppl; abstr 4006).
39. Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest 2013; 123: 4144-4157.
40. Agarwal A, MacKenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW et al. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res 2014; 20: 2092-2103.
41. von Lindern M, van Baal S, Wiegant J, Raap A, Hagemeijer A, Grosveld G. Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene. Mol Cell Biol 1992; 12: 3346-3355.
42. Li M, Guo H, Damuni Z. Purification and characterization of two potent heat-stable protein inhibitors of protein phosphatase 2A from bovine kidney. Biochemistry. 1995; 34: 1988-1996.
43. Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med 2012; 366: 339-347.
44. Issa NP, Hentati A. VZV encephalitis that developed in an immunized patient during fingolimod therapy. Neurology 2015; 84: 99-100.
45. Muto S, Senda M, Akai Y, Sato L, Suzuki T, Nagai R et al. Relationship between the structure of SET/TAF-Ibeta/INHAT and its histone chaperone activity. Proc Natl Acad Sci USA 2007; 104: 4285-4290.
46. Li L, Elledge SJ, Peterson CA, Bales ES, Legerski RJ. Specific association between the human DNA repair proteins XPA and ERCC1. Proc Natl Acad Sci USA 1994; 91: 5012-5016.
47. Eisenmann DM, Chapon C, Roberts SM, Dollard C, Winston F. The Saccharomyces cerevisiae SPT8 gene encodes a very acidic protein that is functionally related to SPT3 and TATA-binding protein. Genetics 1994; 137: 647-657.
48. Pippa R, Dominguez A, Christensen DJ, Moreno-Miralles I, Blanco-Prieto MJ, Vitek MP et al. Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity. Leukemia 2014; 28: 1915-1918.
49. Zhai B, Hu F, Jiang X, Xu J, Zhao D, Liu B et al. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. Mol Cancer Ther 2014; 13: 1589-1598.
50. Torti D, Trusolino L. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med 2011; 3: 623-636.
51. Tai WT, Shiau CW, Chen PJ, Chu PY, Huang HP, Liu CY et al. Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma. Hepatology (Baltimore, MD) 2014; 59: 190-201.